Belatacept
- Generic Name
- Belatacept
- Brand Names
- Nulojix
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 706808-37-9
- Unique Ingredient Identifier
- E3B2GI648A
- Background
Belatacept is a soluble fusion protein, which links the extracellular domain of human cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) to the modified Fc (hinge, CH2, and CH3 domains) portion of human immunoglobulin G1 (IgG1). Structurally, abatacept is a glycosylated fusion protein with a MALDI-MS molecular weight of 92,300 Da and it is a homodimer of t...
- Indication
For prophylaxis of organ rejection. It is also used concomitantly with basiliximumab for induction therapy, mycophenolate, and corticosteriods in kidney transplant recepients that are seropositive for the Epstein-Barr virus.
- Associated Conditions
- Kidney Transplant Rejection
- Associated Therapies
- -
Treg Modulation With CD28 and IL-6 Receptor Antagonists
- Conditions
- Interventions
- First Posted Date
- 2019-08-26
- Last Posted Date
- 2024-10-09
- Target Recruit Count
- 24
- Registration Number
- NCT04066114
- Locations
- 🇺🇸
Cleveland Clinic Foundation: Transplantation, Cleveland, Ohio, United States
🇺🇸University of California San Francisco School of Medicine: Transplantation, San Francisco, California, United States
🇺🇸University of Alabama School of Medicine: Transplantation, Birmingham, Alabama, United States
A Study to Evaluate the Safety and Efficacy of Dual Costimulation Blockade With VIB4920 and Belatacept for Prophylaxis of Allograft Rejection in Adults Receiving a Kidney Transplant
- Conditions
- Interventions
- First Posted Date
- 2019-08-06
- Last Posted Date
- 2023-10-10
- Lead Sponsor
- Viela Bio (acquired by Horizon Therapeutics)
- Target Recruit Count
- 25
- Registration Number
- NCT04046549
- Locations
- 🇺🇸
University of California, San Francisco, San Francisco, California, United States
🇺🇸Keck Medical Center of USC, Los Angeles, California, United States
🇺🇸Duke University School of Medicine, Durham, North Carolina, United States
Lung Transplant Plasmapheresis/Belatacept/Carfilzomib for Antibody Mediated Rejection and Desensitization
- Conditions
- Interventions
- First Posted Date
- 2019-01-15
- Last Posted Date
- 2019-05-02
- Lead Sponsor
- Duke University
- Registration Number
- NCT03805178
Tolerance by Engaging Antigen During Cellular Homeostasis
- First Posted Date
- 2018-04-20
- Last Posted Date
- 2024-01-26
- Target Recruit Count
- 8
- Registration Number
- NCT03504241
- Locations
- 🇺🇸
Duke University Health System, Durham, North Carolina, United States
Belatacept Pilot Study in Lung Transplantation Immunosuppression in Lung Transplantation
- First Posted Date
- 2018-01-02
- Last Posted Date
- 2022-11-25
- Lead Sponsor
- Washington University School of Medicine
- Target Recruit Count
- 27
- Registration Number
- NCT03388008
- Locations
- 🇺🇸
Washington University School of Medicine, Saint Louis, Missouri, United States
🇺🇸Houston Methodist Hospital, Houston, Texas, United States
A Study Using Healthy Volunteers Comparing Belatacept Which Has Been Manufactured By 2 Different Processes
- First Posted Date
- 2017-12-15
- Last Posted Date
- 2019-07-24
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 84
- Registration Number
- NCT03375138
- Locations
- 🇺🇸
PPD Austin Clinic, Austin, Texas, United States
🇺🇸Covance, Inc., Dallas, Texas, United States
Precision Medicine Offers Belatacept Monotherapy
- First Posted Date
- 2016-10-20
- Last Posted Date
- 2022-12-06
- Lead Sponsor
- University of California, San Francisco
- Registration Number
- NCT02939365
Bela 8 Week Dosing
- First Posted Date
- 2015-09-25
- Last Posted Date
- 2020-09-18
- Lead Sponsor
- Emory University
- Target Recruit Count
- 166
- Registration Number
- NCT02560558
- Locations
- 🇺🇸
Emory University Hospital, Atlanta, Georgia, United States
🇺🇸Emory Clinic, Atlanta, Georgia, United States
Belatacept Conversion in Proteinuric Kidney Transplant Recipients
- First Posted Date
- 2014-12-30
- Last Posted Date
- 2022-11-09
- Lead Sponsor
- Brigham and Women's Hospital
- Target Recruit Count
- 15
- Registration Number
- NCT02327403
- Locations
- 🇺🇸
Brigham and Women's Hospital, Boston, Massachusetts, United States
Renal Allograft Tolerance Through Mixed Chimerism (Belatacept)
- First Posted Date
- 2014-12-11
- Last Posted Date
- 2021-10-25
- Lead Sponsor
- Massachusetts General Hospital
- Target Recruit Count
- 2
- Registration Number
- NCT02314403
- Locations
- 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.